Generated by AI
Omeros Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. The company concentrates on immunologic and complement-mediated diseases, along with selected orphan and rare indications affecting inflammation, coagulopathies, and central nervous system disorders. Its portfolio includes commercial and development-stage programs designed to address unmet medical needs across hematology, nephrology, immunology, oncology, and addiction-related conditions. Omeros also works on targeted therapeutics that modulate the complement pathway, a key part of the immune system involved in several serious diseases. Headquartered in Seattle, Washington, Omeros Corp. plays a specialized role in the biotechnology market by advancing differentiated therapies from research through commercialization.
WebsiteThe Omeros Building
Seattle, WA, 98119
United States
The latest articles about OMER.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Oct 16's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about OMER also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.